Delivery Order SPE2DB24D2003-SPE2DB25FXJB0
Award Date 5/27/25
Potential Completion Date 5/28/25
Potential Value $69K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $29,860.78 for Dupixent 300 mg/2 ml syringes on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price contract, which is not set-aside, will be performed at the company's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, asthma, and other inflammatory conditions, making...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for Dupixent 200mg/1.14ml syringes totaling $11,966.22 under a firm fixed price contract. This competitively awarded, non-set-aside delivery order is scheduled for completion by August 15, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat...
- The Defense Logistics Agency awarded a $79,236.52 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL syringes on September 4, 2025, with completion targeted for September 5, 2025. This competitive, firm fixed-price award carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various inflammatory conditions, including asthma, atopic...
- The Defense Logistics Agency awarded a $14,845.54 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on July 23, 2025, with completion scheduled for July 24, 2025. This competitively awarded, firm fixed price contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication primarily used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a $31,152.11 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 200 mg/1.14 mL syringes with a completion date of August 5, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $14,592.80 for Dupixent 300 mg/2 ml syringes on July 7, 2025, with completion scheduled for July 8, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, eosinophilic asthma, and chronic...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,709.46 for Dupixent 300 mg/2 ml syringes on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other allergic conditions,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $26,522.23 for Dupixent (dupilumab) 300 mg/2 mL syringes on August 26, 2025, with an ultimate completion date of August 27, 2025. This firm fixed-price, competitively awarded contract involves no set-aside designation and is being performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $13,593.94 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This firm fixed-price, non-set-aside contract is classified as a delivery order with an ultimate completion date of September 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication primarily used to treat moderate-to-severe...
- The Defense Logistics Agency awarded a delivery order valued at $14,708.04 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on September 3, 2025, with a completion date of September 4, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other allergic inflammatory...